Document Detail

Problem of patent ductus arteriosus in premature infants.
MedLine Citation:
PMID:  724268     Owner:  NLM     Status:  MEDLINE    
Postanatal closure of the ductus arteriosus depends on the level of O2 to which it is exposed. Certain vasoactive substances may also play a role in this constriction. The response to O2 is not as well developed in immature fetal animals and this probably explains the high incidence of patent ductus arteriosus (PDA) in premature human infants. The magnitude of shunting through a PDA depends on its size and the relationship between the pulmonary and systemic vascular resistances. Factors affecting the pulmonary vascular resistance (such as hypoxia) will therefore affect the shunt. The ability of the infant to handle the volume overload also depends on maturity of the infant since myocardial development may not be complete even at term. The clinical manifestations and management of PDA with and without pulmonary disease are described. Recent attempts at pharmacological closure of the PDA are presented.
M A Heymann; J I Hoffman
Related Documents :
603878 - Postnatal ultrastructural changes in the cat myocardium: a morphometric study.
12804488 - Indomethacin for asymptomatic patent ductus arteriosus in preterm infants.
18822428 - Randomized trial of milrinone versus placebo for prevention of low systemic blood flow ...
15843268 - Comparison of clinical criteria with echocardiographic findings in diagnosing pda in pr...
2840828 - Expanding the spectrum of the perlman syndrome.
23374038 - Room air resuscitation and targeted oxygenation for infants at birth in the delivery room.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Paediatrician     Volume:  7     ISSN:  -     ISO Abbreviation:  Paediatrician     Publication Date:  1978  
Date Detail:
Created Date:  1979-02-21     Completed Date:  1979-02-21     Revised Date:  2014-07-24    
Medline Journal Info:
Nlm Unique ID:  0352330     Medline TA:  Paediatrician     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  3-17     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / therapeutic use
Blood Pressure / drug effects
Coronary Circulation / drug effects
Ductus Arteriosus, Patent / diagnosis,  physiopathology*,  therapy
Heart Failure / physiopathology
Heart Rate / drug effects
Indomethacin / therapeutic use
Infant, Low Birth Weight
Infant, Newborn
Infant, Premature, Diseases / therapy
Muscle Contraction / drug effects
Muscle, Smooth / physiopathology
Myocardial Contraction / drug effects
Oxygen / blood
Pulmonary Circulation / drug effects
Respiratory Distress Syndrome, Newborn / physiopathology
Vascular Resistance / drug effects
Reg. No./Substance:
R16CO5Y76E/Aspirin; S88TT14065/Oxygen; XXE1CET956/Indomethacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Current status of open heart surgery in infancy.
Next Document:  Surgical treatment of complex congenital heart defects: recent developments with valved external con...